|Friday, 29 September 2017, 08:00 HKT/SGT|
|- Multi-arm trial targets sub-population of advanced lung, and head and neck cancer patients|
- Medium term objective is to transform non-responders into checkpoint inhibitor responders while improving patient benefits
- Trial aims to evaluate the ability of NBTXR3 to generate an abscopal effect
- Expands the potential for NBTXR3, including recurrent or metastatic disease
- Trial should start with combining NBTXR3 with any approved checkpoint inhibitors in head and neck squamous cell carcinoma or non-small cell lung cancer
Paris, France and Cambridge, Massachusetts, USA, Sept 29, 2017 - (ACN Newswire) - NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, announced today its intention to start a new trial in the company's immuno-oncology (IO) program. The trial is aimed at expanding the potential of NBTXR3 to recurrent and metastatic disease.
The trial would target recurrent head and neck, and metastatic lung cancer patients. Studies indicate that the vast majority of oncology patients do not respond to checkpoint inhibitors.
Nanobiotix's plan for this U.S.-based trial is to evaluate its lead product, NBTXR3, in combination with immune checkpoint inhibitors, with the aim of unlocking their vast potential to convert refractory patients into responders.
Elsa Borghi, Nanobiotix's Chief Medical Officer commented: "The immunomodulatory effects of NBTXR3 have the potential to transform non-responders into responders. This approach could be practice-changing, as it addresses unmet medical needs through directed tumor in situ vaccination."
For the past decade, there has been excitement around immuno-oncology agents' capacity to boost the immune system's response, priming it for an active attack against tumor cells. The response to checkpoint inhibitors in so-called "hot" tumors, infiltrated by T-cells and characterized by an inflammatory profile, has been striking with long-lasting clinical benefits in many cancer patients.
However, many tumors exhibit little or no response to therapies targeting the immune system and are considered "cold", due to a lack of immunogenicity.
According to published data, only 15 to 20% of non-small-cell lung cancer patients (NSCLC), and 13 to 22% of head and neck squamous cell carcinoma patients (NHSCC) respond to immunotherapy treatments.
Moreover, treatment using checkpoint inhibitors is generally not effective against all tumor types ("cold" tumors devoid of T-cell saturation, PD-1/PDL-1 blockage cannot drive an anti-cancer response).
The physical mode of action and subsequent cell death generated by NBTXR3 induce a different immunogenicity compared to radiotherapy and chemotherapy. This could be the key to significantly increasing the number of cancer patients who can benefit from immuno-oncology strategies.
As Nanobiotix reported earlier this year at ASCO 2017, NBTXR3 activated by radiotherapy was shown to induce a specific adaptive immune pattern that could potentially convert a non-responder into an immune-responsive patient receptive to treatment with checkpoint inhibitors.
On top of NBTXR3's core developments as a single agent across seven oncology indications, Nanobiotix's Immuno-Oncology combination program opens the door to new developments, potential new indications, and important value creation opportunities.
About Nanobiotix's immuno-oncology research program
Many IO combination strategies focus on 'priming' the tumor, which is now becoming a prerequisite of turning a "cold" tumor into a "hot" tumor.
Compared to other modalities that could be used for priming the tumor, NBTXR3 could have a number of advantages: the physical and universal mode of action that could be used widely across oncology, the one-time local injection and good fit within existing medical practice already used as a basis for cancer treatment, as well as a very good chronic safety profile and well-established manufacturing process.
After 18 months of development, the Company presented preclinical proof of concept demonstrating that NBTXR3 actively stimulates the host immune system to attack tumor cells.
Recently, Nanobiotix presented new translational data. Taken together, these non-clinical and preliminary clinical results confirm that NBTXR3 plus radiotherapy could efficiently prime an adaptive antitumor immune response, turning "cold" tumors in "hot" tumors. Additionally, these results suggest that the physically-induced response and subsequent immune activation triggered by the NBTXR3 treatment could be generic. Results suggests that NBTXR3 with radiotherapy could transform tumors into an effective in situ vaccine, opening up very promising perspectives in the treatment of local cancer and metastases.
The new clinical data and previous pre-clinical data indicate that NBTXR3 could play a key role in oncology and could become a backbone of immuno-oncology.
On top of the Company's core development activities, these findings could open new collaborations for NBTXR3 through combinations with other immuno-oncology drugs.
About NANOBIOTIX: www.nanobiotix.com
Nanobiotix (Euronext: NANO / ISIN: FR0011341205) is a late clinical-stage nanomedicine company pioneering novel approaches for the treatment of cancer. The Company's first-in-class, proprietary technology, NanoXray, enhances radiotherapy energy with a view to providing a new, more efficient treatment for cancer patients.
NanoXray products are compatible with current radiotherapy treatments and are meant to treat potentially a wide variety of solid tumors including soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, breast cancer, glioblastoma, etc., via multiple routes of administration.
NBTXR3 is being evaluated in: soft tissue sarcoma (STS), head and neck cancers, prostate cancer, and liver cancers (primary and metastases). Additionally, head and neck cancer and rectal cancer trials led by Nanobiotix's Taiwanese partner, PharmaEngine, are underway in the Asia Pacific region. The Company filed in August 2016 for market approval (CE Marking) in Europe for its lead product NBTXR3.
In 2016 the Company started a new preclinical research program in Immuno-oncology with its lead product NBTXR3, which could have the potential to bring a new dimension to cancer immunotherapies.
Nanobiotix is listed on the regulated market of Euronext in Paris (ISIN: FR0011341205, Euronext ticker: NANO, Bloomberg: NANO: FP). The Company's Headquarters is based in Paris, France, with a U.S. affiliate in Cambridge, MA.
Director, Communications & Public Affairs
+33 (0)1 40 26 07 55
email@example.com / firstname.lastname@example.org
Director, Investor Relations
+1 (646) 241-4400
email@example.com / firstname.lastname@example.org
France - Springbok Consultants
+33 (0)6 71 58 00 34
United States - RooneyPartners
+1 (212) 223-4017
This press release contains certain forward-looking statements concerning Nanobiotix and its business. Such forward-looking statements are based on assumptions that Nanobiotix considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the reference document of Nanobiotix filed with the French Financial Markets Authority (Autorite des Marches Financiers) under number D.17-0470 on April 28, 2017 (a copy of which is available on www.nanobiotix.com) and to the development of economic conditions, financial markets and the markets in which Nanobiotix operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Nanobiotix or not currently considered material by Nanobiotix. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Nanobiotix to be materially different from such forward-looking statements.
This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Nanobiotix shares in any country. At the moment NBTXR3 does not bear a CE mark and is not permitted to be placed on the market or put into service until NBTXR3 has obtained a CE mark.
Sept 29, 2017 08:00 HKT/SGT
Topic: Clinical Trial Results
Sectors: Science & Research, BioTech, HealthCare
From the Asia Corporate News Network
Copyright © 2018 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|Jan 22, 2018 15:00 HKT/SGT|
Nanobiotix Presents First Promising Data from Phase I/II Liver Cancers Trial of NBTXR3 at the American Society of Clinical Oncology Gastrointestinal Annual Meeting|
|Jan 11, 2018 15:00 HKT/SGT|
Nanobiotix Partners with Providence Cancer Institute to run Immunotherapeutic Preclinical Research in Pancreatic Cancers|
|Dec 26, 2017 15:50 HKT/SGT|
Nanobiotix: 2017 review and 2018 expected milestones|
|Dec 26, 2017 15:15 HKT/SGT|
FDA approves Nanobiotix's first Immuno-Oncology trial|
|Nov 13, 2017 15:00 HKT/SGT|
Nanobiotix presented new clinical and pre-clinical data confirming NBTXR3's significant potential role in Immuno-Oncology at SITC Annual Meeting|
|Nov 10, 2017 08:30 HKT/SGT|
Nanobiotix provides update on the global development of its lead product NBTXR3|
|Oct 23, 2017 14:00 HKT/SGT|
Nanobiotix Completes Patient Inclusion for Phase II/III Trial of NBTXR3 in Soft Tissue Sarcoma|
|Sept 1, 2017 01:30 HKT/SGT|
Nanobiotix half year results for the six months ended 30 June 2017|
|June 16, 2017 06:00 HKT/SGT|
NANOBIOTIX: New Translational Data Presented at ASTRO, NCI and SITC's Immunotherapy Workshop|
|June 6, 2017 00:00 HKT/SGT|
NANOBIOTIX: Promising Data from Phase I/II Head and Neck Cancer Trial with NBTXR3 Presented at the American Society of Clinical Oncology's Annual Meeting|
|More news >>|